Cigna Group (NYSE:CI) Stock Has Consensus Price Target of $338.24 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Cigna Group, with 15 buy ratings and 8 holds. The average 12-month price target is $338.24, including Guggenheim’s recent increase to $361.
• Cigna reported quarterly adjusted EPS of $7.78, exceeding expectations of $7.60, while revenue rose 6.7% year over year to $71.56 billion, above the $70.14 billion consensus.
• The stock opened at $306.93 and has a market capitalization of approximately $81.1 billion. Insiders sold 22,730 shares worth $6.29 million in the latest quarter, while institutional investors own nearly 87% of the company.

Cigna Group (NYSE:CI - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-three brokerages that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $338.24.

A number of equities research analysts recently weighed in on the company. Guggenheim boosted their price objective on Cigna Group from $338.00 to $361.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Barclays increased their target price on Cigna Group from $304.00 to $310.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Sanford C. Bernstein reissued an "outperform" rating on shares of Cigna Group in a research note on Friday, October 2nd. Piper Sandler restated an "overweight" rating on shares of Cigna Group in a report on Friday. Finally, Wall Street Zen upgraded Cigna Group from a "hold" rating to a "buy" rating in a report on Saturday, September 26th.

Cigna Group Stock Performance

Shares of Cigna Group stock opened at $306.93 on Friday. The company's 50 day moving average price is $281.72 and its two-hundred day moving average price is $283.21. The firm has a market capitalization of $81.10 billion, a P/E ratio of 12.70, a P/E/G ratio of 1.04 and a beta of 0.29. Cigna Group has a fifty-two week low of $239.51 and a fifty-two week high of $316.27. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.76 and a quick ratio of 0.76.

Cigna Group (NYSE:CI - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.60 by $0.18. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The company had revenue of $71.56 billion during the quarter, compared to the consensus estimate of $70.14 billion. During the same period in the prior year, the business earned $7.20 earnings per share. The company's revenue for the quarter was up 6.7% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.450- EPS. On average, equities analysts forecast that Cigna Group will post 30.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cigna Group news, insider Everett Neville sold 617 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $284.05, for a total value of $175,258.85. Following the completion of the transaction, the insider directly owned 5,053 shares in the company, valued at approximately $1,435,304.65. This represents a 10.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nicole S. Jones sold 19,436 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $276.27, for a total transaction of $5,369,583.72. Following the completion of the transaction, the insider owned 27,256 shares of the company's stock, valued at approximately $7,530,015.12. This trade represents a 41.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 22,730 shares of company stock valued at $6,293,359. 0.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cigna Group

Hedge funds have recently modified their holdings of the business. Osbon Capital Management LLC bought a new position in Cigna Group during the 2nd quarter worth $26,000. Cedar Mountain Advisors LLC lifted its stake in shares of Cigna Group by 161.9% in the first quarter. Cedar Mountain Advisors LLC now owns 110 shares of the health services provider's stock worth $29,000 after acquiring an additional 68 shares during the period. Johnson Financial Group Inc. bought a new stake in Cigna Group in the second quarter valued at approximately $29,000. Fiduciary Financial Advisors bought a new stake in Cigna Group in the second quarter valued at approximately $29,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Cigna Group in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 86.99% of the company's stock.

About Cigna Group

The Cigna Group NYSE: CI is a global health services company that provides insurance coverage, health care benefits and related services. Its operations are primarily organized through Cigna Healthcare, which offers medical, pharmacy, dental, behavioral health and other benefit programs to employers, government organizations and individuals, primarily in the United States.

The company also operates Evernorth Health Services, a health services platform that includes pharmacy benefit management, specialty pharmacy, care management and health-care delivery capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.